DSI
KDNY

Daiwa SB Investments’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Daiwa SB Investments’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,810
Closed -$160K – 254
2017
Q2 		$160K Sell
2,810
-40
-1% -$2.01K 0.04% 129
2017
Q1 		$153K Buy
+2,850
New +$161K 0.04% 143

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Daiwa SB Investments's KDNY Position: Q3 2017 in Review

Daiwa SB Investments sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2017, closing a stake of 2,810 shares — an estimated $160K sold.

Daiwa SB Investments first reported a position in KDNY in Q1 2017 and held it in 2 quarters. The position peaked at $160K in Q2 2017. 90 funds tracked by Wall St. Rank hold KDNY as of Q3 2017.

  • Daiwa SB Investments reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Daiwa SB Investments sold 2,810 Chinook Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $160K.
  • Daiwa SB Investments first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Daiwa SB Investments's Chinook Therapeutics, Inc. Common Stock position peaked at $160K in Q2 2017.
  • 90 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Daiwa SB Investments's 13F filing for Q3 2017, filed 13 Oct 2017.